Explore our workshops at Corporate Workshop Day - October 31, 2018
Promega will be presenting three workshops at the AMP 2018 Corporate Workshop Day, October 31, 2018. Join us to learn about the many ways our solutions can be used for your research. By attending a workshop and visiting us at booth #319 you will be entered twice to win a FitBit Versa.
Tracking MSI status in liquid biopsies from MSI-H colorectal cancer patients on immunotherapy
8:00 - 8:50am | Room 301B
Presented by: Pamela Ward PhD, Scientific Director, University of Southern California Clinical Laboratories, Molecular Pathology
The success of checkpoint inhibitors targeting programmed cell death protein-1, programmed cell death ligand-1, and cytotoxic T lymphocyte antigen-4 in the treatment of patients with colorectal cancers displaying microsatellite instability underscores the need for novel technologies to evaluate the progression of such instability as a means of monitoring therapeutic response. As serial tumor specimens are usually not available while patients are on therapy, we have conducted research in monitoring the MSI status of liquid biopsies from MSI-H colorectal cancer patients to determine if MSI has the potential to be used as a biomarker for immunotherapy response.
Rapid cancer testing as an integral part of precision oncology
1:00 - 1:50pm | Room 301A
Presented by: Dora Dias-Santagata PhD, FACMG, Assistant Professor of Pathology, Harvard Medical School; Assistant Lab Scientist, Massachusetts General Hospital; Co-Director, Translational Research Laboratory, Center for Integrated Diagnostics Molecular Pathology Unit, Massachusetts General Hospital
Next Generation Sequencing (NGS) plays a critical role for comprehensive assessment of relevant mutations in cancer. However, turnaround times for NGS – in some settings - are still too slow (e.g., acute leukemia, aggressive end-stage NSCLC). In this presentation, Dr. Dias-Santagata will describe the development of several rapid cancer testing workflows for sample preparation to deliver timely, comprehensive NGS data. As an additional function of the workflow development, streamlined machine-learning powered NGS results in improved reporting times and integrated data analytics.
Why Microsatellite Instability (MSI) characterization of tumors by PCR is still the gold standard in a world of NGS
3:00 - 3:50pm | Room 221CD
Presented by: Jeff Bacher, Sr. Research Scientist, Promega Corporation
AMP, CAP and the NCI have recognized the prognostic utility of MSI characterization for decades. In 2017, the FDA named MSI as a tumor biomarker for immunotherapeutic treatment of all cancers types, thus extending the utility of this trusted biomarker for an exciting new indication in the selection of patients with unrespectable or metastatic MSI-High solid tumors. This presentation will cover both basic and advanced topics of characterizing MSI status of tumor tissue using PCR and capillary electrophoresis and why this method is still the gold standard globally and likely to remain so into the future.
Join us in the exhibit hall at booth #319 to see our workflows in action. Let us know where your pain points arise & we’ll help to show you how our solutions can make sure you avoid any misadventures with your sample. Plus, if you chat with one of our representatives about your research you'll be entered to win a FitBit Versa. We look forward to speaking and collaborating with you!
- Thursday, November 1
- 11:30am – 4:30pm – Exhibit Hall Open
- 5:45pm – 7:00pm – Welcome Reception in the Exhibit Hall
- Friday, November 2
- 9:00am – 4:00pm – Exhibit Hall Open
- Saturday, November 3
- 9:00am – 1:30pm – Exhibit Hall Open